Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) dated April 21, 2015, announces significant structural changes to Perrigo Company plc's financial reporting framework. The Company is transitioning its fiscal year-end to align with the calendar year (January 1 to December 31), effective January 1, 2016. Additionally, following the acquisition of Omega Pharma NV, the Company has reorganized its reporting segments to better reflect its operational structure.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the main text. Instead, it references Exhibits 99.1 and 99.2, which contain recast historical financial statements and metrics for periods ranging from 2010 to 2014. These exhibits present data on a consolidated basis and under the new segment structure to aid comparability.
Material Changes Versus Prior Period
The primary material changes involve reporting methodology rather than operational performance:
- Fiscal Year Change: The Company will adopt a calendar year-end starting in 2016. Full-year guidance will be provided on a calendar basis beginning with the fiscal 2015 third quarter.
- Segment Reclassification: Reporting segments have been redefined as follows:
- Consumer Healthcare: Combines legacy Consumer Healthcare, Nutritionals (Infant nutrition and VMS), and Israel Pharmaceuticals and Diagnostics.
- Branded Consumer Healthcare: Comprises the newly acquired Omega business.
- Rx Pharmaceuticals: Continues to comprise the legacy Rx Pharmaceuticals business.
- Specialty Sciences: Continues to comprise royalties from Tysabri.
- Other: Comprises the legacy Active Pharmaceutical Ingredients (API) business.
- Impact on Historical Data: The Company states these changes have no impact on historical consolidated financial position, results of operations, or cash flows. Selected statements have been recast for comparability but do not constitute a restatement of previously issued financial statements.
Guidance, Outlook, and Non-GAAP Measures
Management utilizes adjusted financial measures (non-GAAP) for planning, forecasting, and evaluating core business performance. The filing lists specific items excluded from reported results to derive these adjusted measures, including:
- Acquisition-related amortization and costs (transaction financing, integration, hedging).
- Restructuring charges and loss contingency accruals.
- Losses on equity method investments and write-offs of IPR&D.
- Inventory step-ups and adjustments to contingent consideration.
- Litigation settlements and escrow settlements.
- Proceeds from the sale of IPR&D projects.
Reconciliations of these non-GAAP measures to the most directly comparable U.S. GAAP measures are provided in Exhibits 99.1 and 99.2.
Investor Verification Checklist
- Review Exhibit 99.1 for recast historical financial statements for calendar years 2010-2011.
- Review Exhibit 99.2 for recast historical financial statements for calendar years 2012-2014 and segment-level data.
- Verify the reconciliation of non-GAAP measures (Operating income, Net income, EPS) to GAAP measures in the exhibits.
- Confirm the timeline for the fiscal year-end transition to ensure accurate comparison of future guidance starting in Q3 2015.
- Consult the Form 10-K for the year ended June 28, 2014, and subsequent 10-Q filings for detailed operational context.